SCHEMBL370547

SCHEMBL370547

FC(F)(Br)C[CH]Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL243489 0.74
SCHEMBL1018844 0.69
SCHEMBL14785207 0.69
SCHEMBL7746761 0.69
SCHEMBL27423450 0.69
SCHEMBL16285766 0.69
SCHEMBL31471492 0.65
SCHEMBL3690276 0.65
SCHEMBL7049892 0.65
SCHEMBL9593435 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 875 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151809-A1 INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME BAYLOR COLLEGE OF MEDICINE (US) 2024-07-18 WO disclosed
WO-2024152000-A1 DISRUPTABLE LINKER COMPOSITIONS, SWITCHABLE BISPECIFIC T CELL NANOENGAGER (SWITCH-BITE) COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-07-18 WO disclosed
CN-118354770-A Flavonoid derivatives having GABAA receptor activity and methods of use 罗特格斯新泽西州立大学 2024-07-16 CN disclosed
CN-118338907-A Lipid Nanoparticle (LNP) compositions and methods of using the same 宾夕法尼亚大学董事会 2024-07-12 CN disclosed
WO-2024145273-A2 N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) 2024-07-04 WO disclosed
EP-4392430-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS Yale University (US) 2024-07-03 EP disclosed
EP-4392168-A1 IONIC LIQUID-BASED COMPOSITE MEMBRANES USING FUNCTIONAL CROSS-LINKERS The Regents of the University of Colorado, a body corporate (US) 2024-07-03 EP disclosed
US-20240208971-A1 INHIBITORS OF KINASE NETWORKS AND USES THEREOF PURDUE RESEARCH FOUNDATION 2024-06-27 US disclosed
US-20240207207-A1 METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES SAN DIEGO STATE UNIV SDSU FOUNDATION DBA SAN DIEGO STATE UNIV RESEARCH FOUNDATION (US) 2024-06-27 US disclosed
EP-3377473-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-06-19 EP disclosed
WO-2010056758-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS FENG YANGBO (US) 2010-05-20 WO disclosed
WO-2010036316-A1 UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS FENG YANGBO (US) 2010-04-01 WO disclosed
WO-2010033466-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE PHENOMIX CORPORATION (US) 2010-03-25 WO disclosed
WO-2010024903-A1 BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS FENG YANGBO (US) 2010-03-04 WO disclosed
US-20100009954-A1 BETA-LACTAMASE INHIBITORY COMPOUNDS SOUTHERN METHODIST UNIVERSITY 2010-01-14 US disclosed
WO-2009139834-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES PONIARD PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed
WO-2009131631-A1 RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS PONIARD PHARMACEUTICALS, INC. (US) 2009-10-29 WO disclosed
WO-2009102876-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE PHENOMIX CORPORATION (US) 2009-08-20 WO disclosed
WO-2009079008-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS FENG YANGBO (US) 2009-06-25 WO disclosed
WO-2009079011-A1 BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-06-25 WO disclosed